» Articles » PMID: 3731687

Changes in Antipyrine and Indocyanine Green Kinetics During Nifedipine, Verapamil, and Diltiazem Therapy

Overview
Publisher Wiley
Specialty Pharmacology
Date 1986 Aug 1
PMID 3731687
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Ten healthy subjects received oral antipyrine and intravenous indocyanine green (ICG) alone and after 5 days of oral nifedipine, diltiazem, and verapamil. Antipyrine clearance decreased during verapamil (range 4% to 26%) and diltiazem (6% to 24%) therapy (P less than 0.001) but did not change during nifedipine treatment. Antipyrine t1/2 also increased during verapamil and diltiazem treatment (P less than 0.001). ICG clearance did not change during diltiazem therapy but increased during dosing with nifedipine and verapamil (P less than 0.05). Estimated liver blood flow (derived from ICG clearance and hematocrit) also increased during verapamil (mean 33%) and nifedipine (mean 27%) treatment (P less than 0.05). Drug interactions with other liver-metabolized drugs may occur during therapy with these calcium antagonists. Nifedipine appears to increase liver blood flow whereas diltiazem inhibits oxidative drug metabolism. Drug interactions with verapamil could involve both mechanisms.

Citing Articles

The influence of nifedipine and captopril on liver blood flow in healthy subjects.

Burggraaf J, Schoemaker R, Kroon J, Cohen A Br J Clin Pharmacol. 1998; 45(5):447-51.

PMID: 9643616 PMC: 1873537. DOI: 10.1046/j.1365-2125.1998.00709.x.


Lack of presystemic metabolism of nifedipine in the rabbit.

du Souich P, Heroux L, Maurice H, Depot M, Caille G J Pharmacokinet Biopharm. 1995; 23(6):567-80.

PMID: 8733947 DOI: 10.1007/BF02353462.


Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.

de Boer A, Kluft C, Kasper F, Kroon J, Schoemaker H, Breimer D Br J Clin Pharmacol. 1993; 36(2):99-104.

PMID: 8398589 PMC: 1364571. DOI: 10.1111/j.1365-2125.1993.tb04203.x.


Dose of midazolam should be reduced during diltiazem and verapamil treatments.

Backman J, Olkkola K, Aranko K, Himberg J, Neuvonen P Br J Clin Pharmacol. 1994; 37(3):221-5.

PMID: 8198928 PMC: 1364750. DOI: 10.1111/j.1365-2125.1994.tb04266.x.


Drug interactions with thrombolytic agents. Current perspectives.

de Boer A, van Griensven J Clin Pharmacokinet. 1995; 28(4):315-26.

PMID: 7648759 DOI: 10.2165/00003088-199528040-00004.